STOCK TITAN

Oncotelic Therapeutcs (OTLC) Stock News, Mar-Apr 2021

OTLC OTC

Oncotelic Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology, immunotherapy and rare-disease therapeutics. Company updates cover its internal drug pipeline, orphan oncology programs, antisense and small molecule injectable drug candidates, and partnerships or joint ventures used to license and co-develop selected candidates.

Recurring OTLC news also includes the PDAOAI AI platform for research, biomarker discovery, regulatory processes and GMP-compliant robotics, the company's 45% interest in GMP Bio and related Sapu Bio and Sapu Nano programs, and completed portfolio actions such as field-specific monetization of N2B nose-to-brain delivery assets.

Rhea-AI Summary

Oncotelic Therapeutics (OTLC) announced positive results from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal™ in India. The trial demonstrated no adverse events requiring treatment discontinuation, with 91% of patients achieving improved conditions. Key findings include normalized vital signs and significant improvements in oxygen saturation and respiratory rates by day 28. PulmoHeal™, developed in partnership with Windlas Biotech, has potential for broad-spectrum antiviral efficacy, confirmed against multiple SARS-CoV-2 variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced a presentation at AACR-2021 discussing a combination therapy using Trabedersen, an anti-sense oligonucleotide targeting TGF-β2, and Proleukin (IL-2) for treating solid cancers. This approach aims to enhance immune response while mitigating IL-2 toxicity. In vitro studies showed reduced cancer cell viability and significant tumor growth delay in humanized mouse models. Oncotelic also received regulatory approval for a phase 1b trial of the OT-101/IL-2 combination, further supporting its innovative cancer treatment pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.70%
Tags
none
-
Rhea-AI Summary

Oncotelic Therapeutics (OTCQB:OTLC) announced a collaboration with the Chopra Foundation and Jiva to host a webinar titled Ayurvedic Perspectives on COVID-19 on April 15, 2021. The event will feature experts discussing various aspects of COVID-19 management, including inflammation and Ayurvedic approaches. Notably, Oncotelic's PulmoHeal includes a mobile app for monitoring respiratory health and a lung therapy supplement that has demonstrated efficacy against COVID-19. The company continues to focus on leveraging AI for health assessments amid the ongoing pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.46%
Tags
covid-19
Rhea-AI Summary

Oncotelic Therapeutics (OTCQB:OTLC), formerly known as Mateon Therapeutics, announced on March 30, 2021, that the Financial Industry Regulatory Authority (FINRA) has approved its name and ticker symbol change. The new ticker symbol, effective immediately, is OTLC, replacing MATN. This follows a corporate action approved by shareholders in August 2020, which included the name change finalized in November 2020. Oncotelic focuses on developing RNA therapeutics and small molecule drugs targeting cancer and infectious diseases, particularly emphasizing rare pediatric cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none

FAQ

What is the current stock price of Oncotelic Therapeutcs (OTLC)?

Oncotelic Therapeutcs (OTLC) last closed at $0.0125.

What is the market cap of Oncotelic Therapeutcs (OTLC)?

The market cap of Oncotelic Therapeutcs (OTLC) is approximately $5.7M.